4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Gurugram, India with about 1,297 employees. Its market capitalization is roughly ₹15 billion. In the fiscal year ended 2026-03-31, JAGSNPHARM reported ₹2.9B in revenue and ₹431M in net income.
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | ₹2.9B | ₹2.7B | ₹2.1B | ₹2.4B | — |
| Gross Profit | ₹1.8B | ₹1.7B | ₹1.3B | ₹1.4B | — |
| Operating Income (EBIT) | ₹486M | ₹429M | ₹216M | ₹343M | — |
| Net Income | ₹431M | ₹554M | ₹225M | ₹267M | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | ₹822M | ₹642M | ₹730M | ₹745M | ₹756M | — |
| Gross Profit | ₹536M | ₹404M | ₹465M | ₹472M | ₹487M | — |
| Operating Income (EBIT) | ₹151M | ₹88M | ₹139M | ₹140M | ₹119M | — |
| Net Income | ₹132M | ₹88M | ₹110M | ₹126M | ₹108M | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (₹167M) | (₹132M) | (₹131M) | — | (₹105M) |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | ₹3.2B | ₹2.8B | ₹2.2B | ₹1.9B | — |
| Total Liabilities | ₹405M | ₹383M | ₹297M | ₹361M | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive JAGSNPHARM viewer.
About TickerBase · Data methodology & sources · Privacy · Terms